340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
If you’re a plaintiffs’ attorney or Big Labor union boss, what better way to cynically target deep-pocketed American businesses than to grossly broaden the definition of who constitutes an “employer?”
Although it understandably flew a bit under the news radar during an eventful past week, the Trump Administration just notched another significant policy victory for American jobs and our economy by rebuffing that campaign.
Specifically, the Trump Administration’s National Labor Relations Board (NLRB) formally withdrew the Biden Administration’s…
